Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial

MARKETWATCH | on Mon, Apr 3, 11:07 AM

Bristol-Myers Sqibb Co. BMY, -0.31%[1] said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial. The combination of the drugs Opdivo and Yervoy is one many Wall Street analysts believe is promising. Two-year overall survival rates for patients with previously untreated advanced melanoma were highest for the combination treatment, or 64%, followed by 59% for Opdivo alone and 45% for Yervoy alone, accordi...

Read the full article

Semantic processing powered by OpenCalais

Use of the DailyMe service and DailyMe web site constitutes acceptance of the Company's Terms of Service and Privacy Policy.

© 2017 DailyMe, Inc. All rights reserved.